1093.HK
1093.HK
HK1093012172
CSPC PHARMA
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±45.2% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).

Beta (Market Relation)
0.71x
Defensive
Volatility (5Y p.a.)
45.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-57.4%
5-Year Horizon
Sharpe Ratio
-0.06
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -3.4%
3 Years 47.9% -42.1% 0.33 +18.1%
5 Years 45.2% -57.4% -0.06 -0.2%
10 Years 43.1% -68.0% 0.12 +7.8%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (45.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -68.0% in the extended horizon.
ende